BMC Medicine (Aug 2018)

Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease

  • Myriam Alexander,
  • A. Katrina Loomis,
  • Jolyon Fairburn-Beech,
  • Johan van der Lei,
  • Talita Duarte-Salles,
  • Daniel Prieto-Alhambra,
  • David Ansell,
  • Alessandro Pasqua,
  • Francesco Lapi,
  • Peter Rijnbeek,
  • Mees Mosseveld,
  • Paul Avillach,
  • Peter Egger,
  • Stuart Kendrick,
  • Dawn M. Waterworth,
  • Naveed Sattar,
  • William Alazawi

DOI
https://doi.org/10.1186/s12916-018-1103-x
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. It affects an estimated 20% of the general population, based on cohort studies of varying size and heterogeneous selection. However, the prevalence and incidence of recorded NAFLD diagnoses in unselected real-world health-care records is unknown. We harmonised health records from four major European territories and assessed age- and sex-specific point prevalence and incidence of NAFLD over the past decade. Methods Data were extracted from The Health Improvement Network (UK), Health Search Database (Italy), Information System for Research in Primary Care (Spain) and Integrated Primary Care Information (Netherlands). Each database uses a different coding system. Prevalence and incidence estimates were pooled across databases by random-effects meta-analysis after a log-transformation. Results Data were available for 17,669,973 adults, of which 176,114 had a recorded diagnosis of NAFLD. Pooled prevalence trebled from 0.60% in 2007 (95% confidence interval: 0.41–0.79) to 1.85% (0.91–2.79) in 2014. Incidence doubled from 1.32 (0.83–1.82) to 2.35 (1.29–3.40) per 1000 person-years. The FIB-4 non-invasive estimate of liver fibrosis could be calculated in 40.6% of patients, of whom 29.6–35.7% had indeterminate or high-risk scores. Conclusions In the largest primary-care record study of its kind to date, rates of recorded NAFLD are much lower than expected suggesting under-diagnosis and under-recording. Despite this, we have identified rising incidence and prevalence of the diagnosis. Improved recognition of NAFLD may identify people who will benefit from risk factor modification or emerging therapies to prevent progression to cardiometabolic and hepatic complications.

Keywords